Mustang Bio FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million

Reuters

03/20

<a href="https://laohu8.com/S/MBIO">Mustang Bio</a> FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million

Mustang Bio published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.
Net loss narrowed to USD 1.92 million, while loss from operations was USD 2.43 million.
Research and development expense was a credit of USD 1.52 million, driven in part by USD 2.1 million of savings from settlements of aged payables, along with lower clinical-trial, outside-services, and license-related costs.
Cash and cash equivalents were USD 17.3 million and interest income was USD 511,000.
Mustang said it believes it has sufficient cash to fund operations for at least 12 months from the date of the filing, and it is exploring an investigator-sponsored, single-institution MB-109 trial at City of Hope that could be initiated in the second quarter of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-032063), on March 19, 2026, and is solely responsible for the information contained therein.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2620427622"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2620427622\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2620427622?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-20 04:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620427622","market":"fut","top_or_hot":-1,"title":"Mustang Bio FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MBIO\">Mustang Bio</a> FY 2025 net loss narrows 88% to USD 1.92 million on R&amp;D expense down 118% to USD -1.52 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Mustang Bio published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Net loss narrowed to USD 1.92 million, while loss from operations was USD 2.43 million.\n        </li>\n<li>\n          Research and development expense was a credit of USD 1.52 million, driven in part by USD 2.1 million of savings from settlements of aged payables, along with lower clinical-trial, outside-services, and license-related costs.\n        </li>\n<li>\n          Cash and cash equivalents were USD 17.3 million and interest income was USD 511,000.\n        </li>\n<li>\n          Mustang said it believes it has sufficient cash to fund operations for at least 12 months from the date of the filing, and it is exploring an investigator-sponsored, single-institution MB-109 trial at City of Hope that could be initiated in the second quarter of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-032063), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mustang Bio FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMustang Bio FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-20 04:09</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MBIO\">Mustang Bio</a> FY 2025 net loss narrows 88% to USD 1.92 million on R&amp;D expense down 118% to USD -1.52 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Mustang Bio published its annual report on Form 10-<a href=\"https://laohu8.com/S/TKKD.SI\">K</a> for the fiscal year ended Dec. 31, 2025.\n        </li>\n<li>\n          Net loss narrowed to USD 1.92 million, while loss from operations was USD 2.43 million.\n        </li>\n<li>\n          Research and development expense was a credit of USD 1.52 million, driven in part by USD 2.1 million of savings from settlements of aged payables, along with lower clinical-trial, outside-services, and license-related costs.\n        </li>\n<li>\n          Cash and cash equivalents were USD 17.3 million and interest income was USD 511,000.\n        </li>\n<li>\n          Mustang said it believes it has sufficient cash to fund operations for at least 12 months from the date of the filing, and it is exploring an investigator-sponsored, single-institution MB-109 trial at City of Hope that could be initiated in the second quarter of 2026.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-032063), on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MBIO","symbol_name":"Mustang Bio, Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6zhgfw:1","article_id":"2620427622","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620427622","pubTimestamp":1773950950,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mustang Bio published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.Net loss narrowed to USD 1.92 million, while loss from operations was USD 2.43 million.Research and development expense was a credit of USD 1.52 million, driven in part by USD 2.1 million of savings from settlements of aged payables, along with lower clinical-trial, outside-services, and license-related costs.Cash and cash equivalents were USD 17.3 million and interest income was USD 511,000.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MBIO":"Mustang Bio, Inc","BK4139":"生物科技","FBIO":"Fortress Biotech Inc."},"translate_title":"Mustang Bio 2025财年净亏损收窄88%至192万美元，研发费用下降118%至-152万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MBIO":0.9,"FBIO":0.9},"content_text":"Mustang Bio FY 2025 net loss narrows 88% to USD 1.92 million on R&D expense down 118% to USD -1.52 million\n    \n\n\n          Mustang Bio published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.\n        \n\n          Net loss narrowed to USD 1.92 million, while loss from operations was USD 2.43 million.\n        \n\n          Research and development expense was a credit of USD 1.52 million, driven in part by USD 2.1 million of savings from settlements of aged payables, along with lower clinical-trial, outside-services, and license-related costs.\n        \n\n          Cash and cash equivalents were USD 17.3 million and interest income was USD 511,000.\n        \n\n          Mustang said it believes it has sufficient cash to fund operations for at least 12 months from the date of the filing, and it is exploring an investigator-sponsored, single-institution MB-109 trial at City of Hope that could be initiated in the second quarter of 2026.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mustang Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-032063), on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}